Page last updated: 2024-09-05

sorafenib and ly-2157299

sorafenib has been researched along with ly-2157299 in 5 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(ly-2157299)
Trials
(ly-2157299)
Recent Studies (post-2010) (ly-2157299)
6,5207305,25112621124

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ly-2157299 (IC50)
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.044
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)0.2716
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.442
Activin receptor type-1BHomo sapiens (human)0.199
TGF-beta receptor type-1Homo sapiens (human)0.0973
TGF-beta receptor type-2Homo sapiens (human)1.3
D(2) dopamine receptorRattus norvegicus (Norway rat)0.405
Mitogen-activated protein kinase 14Homo sapiens (human)0.4736

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A1
Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J1
Benhadji, KA; Ikeda, M; Inoue, K; Lahn, MMF; Morimoto, M; Sakai, D; Tajimi, M1
Assenat, E; Benhadji, KA; Cleverly, A; Faivre, S; Galle, PR; Gane, E; Giannelli, G; Gueorguieva, I; Hourmand, IO; Kelley, RK; Lahn, M; Merle, P; Siebler, J; Zhao, Y1

Trials

2 trial(s) available for sorafenib and ly-2157299

ArticleYear
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
    Investigational new drugs, 2019, Volume: 37, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Sorafenib; Tissue Distribution

2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Clinical and translational gastroenterology, 2019, Volume: 10, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Safety; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome

2019

Other Studies

3 other study(ies) available for sorafenib and ly-2157299

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1

2015
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta

2017